RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth R. Packnett (Author), Isabelle H. Winer (Author), Heather Larkin (Author), Abiola Oladapo (Author), Tara Gonzales (Author), Matthew Wojdyla (Author), Mitchell Goldstein (Author), Vincent C. Smith (Author)
Format: Book
Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items